Background Epidemiologic studies have yet to provide consistent evidence to support a protective effect of aspirin and other non-steroidal anti-inflammatory drugs (NSAID) on the incidence of breast cancer. Objective We evaluated the relations of current use of aspirin, non-aspirin NSAIDs, and acetaminophen with breast cancer incidence in the Black Women's Health Study. Methods Biennial follow-up of 59,000 study participants began in 1995. During 558,600 person-years of follow-up through 2007, 1,275 breast cancer cases were identified. Using Cox proportional hazards regression, we estimated incidence rate ratios (IRR) and 95% confidence intervals (CI) for associations of current and former use of aspirin, other NSAIDs, and acetaminophen with incident breast cancer. Results After adjustment for age, education, body mass index at age 18, physical activity, female hormone use, current smoking, and other NSAID use, the IRRs were 0.79 (95% CI = 0.66, 0.95) for current aspirin use and 0.68 (95% CI = 0.50, 0.92) for C5 years of aspirin use. Similar associations were observed for acetaminophen use.
Introduction
Aspirin, a non-steroidal anti-inflammatory drug (NSAID), has been consistently associated with a reduced risk of colon cancer [1] [2] [3] [4] [5] , and it has been hypothesized that aspirin and non-aspirin NSAIDs might inhibit the development and progression of breast cancer tumors [3] .
NSAIDs may act on cancer development through the cyclooxygenase (COX) enzyme system. While COX-1 is normally expressed in most human tissues, COX-2 is expressed in response to the inflammatory process (growth factors, oncogenes, and cytokines) [6] . COX-2 concentrations are undetectable in normal breast tissue, but are overexpressed [7, 8] in breast tumors by approximately 40%, and in ductal carcinoma in situ by as much as 80% [9] . COX-2 promotes the production of prostaglandins and leads to an increase in the production of cyclic adenosine monophosphate (cAMP) in breast adipose stromal cells to induce aromatase activity [10] . Aromatase activity enhances the synthesis of estrogen by converting androgen to estrogen in breast tissue [3] , which increases cell proliferation in tumor cells [11] . NSAIDs may block the COX-2 enzyme to decrease aromatase activity, which reduces levels of prostaglandin, estrogen, and prolactin [10] , and could decrease carcinogenesis by increasing apoptosis and decreasing cell proliferation, angiogenesis, and metastasis [6] .
Perhaps because of differences in the assessment of dose, duration, and induction period, epidemiologic studies have not provided consistent evidence to support or refute a protective effect of aspirin and other NSAIDs on the incidence of breast cancer. Several large prospective studies observed an inverse association of aspirin or NSAID use with breast cancer risk [12] [13] [14] [15] , while findings were null in several other large prospective studies [16] [17] [18] [19] [20] [21] [22] , including a randomized controlled trial of low-dose aspirin and breast cancer [21, 22] . Only two studies have specifically reported results among African American women [19, 23] . In the Carolina Breast Cancer Study, a case-control study, there was a stronger inverse association between NSAID use and breast cancer among African American women than White women [23] , whereas there was no association between aspirin and breast cancer among African American women in the Multiethnic Cohort study [19] . Neither of these two studies evaluated aspirin or NSAID use that was updated over time nor did these studies evaluate the use of acetaminophen in African American women.
Given the inconsistent findings for the association between NSAID use and breast cancer, and the limited number of studies conducted in African American women, we evaluated the association of regular aspirin use with the incidence of breast cancer in prospective data from the Black Women's Health Study (BWHS). We also assessed non-aspirin NSAIDs and acetaminophen use.
Materials and methods

Study population
The BWHS is a prospective cohort study of 59,000 African American women aged 21 through 69 years at entry in 1995 [24] . Women were recruited from 17 states across the mainland United States. Information on demographic and lifestyle factors, reproductive history, medical conditions, and medications was collected in the baseline questionnaire. Mortality information was obtained through the National Death Index, postal service, and friends and relatives. The cohort is followed biennially by mailed questionnaire, and 80% of the original cohort had been followed through 2007.
Women who did not complete at least one follow-up questionnaire (n = 53), had prevalent cancer at baseline (n = 1,414), or did not complete the baseline question on aspirin use (n = 4,409) were excluded from this study.
The Boston University Institutional Review Board approved this study.
Analgesic medication use
Self-reported regular aspirin use was collected in the baseline and in each follow-up questionnaire. On the baseline questionnaire, women reported whether or not they were currently using aspirin C3 days per week (regular use) and for how many years they had been taking it on a regular basis (\1, 1, 2, 3-4, C5 years). In a similar question, women were asked to report acetaminophen use. Other NSAIDs were identified through an open-text question that asked women to list any other medications they were taking C3 days per week; the question did not ask about the duration of such use. Each follow-up questionnaire specifically asked women to report aspirin and acetaminophen use C3 days per week and also included the open-text medication question. The 2005 follow-up questionnaire also specifically asked participants to report use of ''baby aspirin'' separate from other aspirin. Medications reported via the open-text question were coded with the Slone Drug Dictionary to identify NSAIDs other than aspirin [25] . Information on dose was not obtained.
Potential confounding variables
Candidate confounding variables were identified a priori from the existing literature [26] [27] [28] [29] [30] [31] [32] . At baseline and in follow-up questionnaires, participants were asked to report if a physician had told them that they had any of a list of medical conditions that included heart attack, angina, stroke, and deep vein thrombosis. In the follow-up questionnaires, they were also asked to report diagnoses of rheumatoid arthritis and osteoarthritis. Educational attainment at baseline was used as a surrogate for socioeconomic status. We used women's self-reported height and weight to calculate body mass index (BMI, weight in kilograms divided by height squared in meters). A woman was considered postmenopausal if she reported having natural menopause or bilateral oophorectomy or if she reported hysterectomy with retention of one or both ovaries and her current age was at least age 57 (90th percentile of age at natural menopause in BWHS). She was considered premenopausal if she reported being premenopausal or if she reported a hysterectomy with retention of one or both ovaries and her current age was less than 43 (10th percentile of age at natural menopause in BWHS). A woman who reported a hysterectomy with retention of one or both ovaries and was 43-56 years of age was classified as having uncertain menopausal status. Family history of breast cancer in a first degree relative (mother, sister) and age at menarche was reported at baseline. Information on parity, age at first birth, oral contraceptive use, female hormone use (i.e., postmenopausal hormone therapy), alcohol consumption, physical activity, smoking, and mammography receipt was collected at baseline and in each follow-up questionnaire.
Breast cancer ascertainment
Among the 59,000 women included in the BWHS cohort, a total of 1,429 breast cancer cases were reported on followup questionnaires from 1997 through 2007. To date, medical records or cancer registry data have been obtained for 1,151 of reported cases, of which 99.4% were confirmed. Because the confirmation rate was very high, we have included cases identified by self-report only.
Statistical analysis
Women were followed from baseline in 1995 until breast cancer diagnosis, death from any cause, loss to follow-up, or the end of follow-up in 2007, whichever came first. Incidence rate ratios (IRR) and 95% confidence intervals (CI) for the associations of use of aspirin, other NSAIDs, and acetaminophen with breast cancer risk were estimated using Cox proportional hazards regression models [33] . We examined current use at baseline (versus non-use) and time-varying use during follow-up (current, former, nonuse). Time-varying, current aspirin use was compared with non-use of aspirin over the course of follow-up. For example, if a woman reported aspirin use in a particular questionnaire, she was classified as a current user for that cycle. Women who reported aspirin use in the subsequent questionnaire remained current users, whereas women who did not report current use in the subsequent questionnaire were classified as former users. Former users could become current users in later questionnaire cycles. Women who did not report aspirin use on any questionnaire were considered non-users. If a woman failed to complete a questionnaire cycle, medication use was coded as missing for that cycle.
Acetaminophen is not an NSAID and has only weak COX inhibiting properties [4] , but our purpose in assessing acetaminophen use in relation to breast cancer risk was to determine whether any observed associations of NSAIDs with breast cancer were specific to NSAIDs or could be due to other factors associated with taking pain medication.
The proportional hazard models were jointly stratified by age (one-year intervals) and questionnaire cycle and included indicator variables to control for education (B12, 13-15, and C16 years), BMI at age 18 (\20, 20-24, 25-29, and C30 kg/m 2 ), vigorous physical activity (none,\5 h per week, C5 h per week), current smoking status (yes, no), and female hormone use (ever, never). All of the variables except BMI at age 18 and years of education were updated in each questionnaire cycle and were treated as timedependent variables in the analysis. Aspirin models were further adjusted for other NSAID use, other NSAID models were adjusted for aspirin use, and acetaminophen models were adjusted for both aspirin and other NSAID use. Adjustment for reproductive history, oral contraceptive use, cardiovascular events (myocardial infarction, angina, stroke, and deep vein thrombosis), and rheumatoid arthritis or osteoarthritis, did not appreciably change the results, and these variables were not included in the final multivariable models. The Andersen-Gill data structure was used to account for the time-dependent nature of pain medication use and covariates in the time-varying analyses [34] .
We stratified by menopausal status and obesity to evaluate whether the associations between aspirin use and breast cancer were modified by these variables.
We conducted several sub-analyses. First, we assessed whether the results differed when comparing each of the specific pain medications to non-use of all pain medications (i.e., current aspirin use compared with non-use of aspirin, other NSAIDs, and acetaminophen). Second, we determined whether including low-dose aspirin (i.e., ''baby aspirin'') reported in the 2005 follow-up questionnaire altered the findings. Last, we accounted for failure to complete one or more questionnaires over follow-up by restricting the analysis to women who completed all of the follow-up questionnaires through 2005.
All statistical tests were two-sided, and analyses were conducted using SAS, version 9.1 (Cary, North Carolina).
Results
After exclusions, the final analytic sample consisted of 53,151 BWHS participants, among whom 1,275 incident breast cancer cases were reported over 558,600 personyears of follow-up through 2007. At baseline, there were 5,427 (10.2%) women who currently used aspirin, 2,257 (4.2%) who were users of other NSAIDs, 7,988 (15.0%) who were acetaminophen users, and 45,887 (86.3%) who did not use any NSAIDs (Table 1) . Among aspirin users, 7.1% also reported use of other NSAIDs and 52.3% reported acetaminophen use. Compared with non-users of aspirin or other NSAIDs, regular users of aspirin, other NSAIDs, and acetaminophen were older, less educated, heavier, less physically active, more likely to use female hormones, more likely to smoke, and had experienced more cardiovascular disease. Aspirin and acetaminophen users had similar distributions of baseline characteristics ( Table 1 ). The point prevalence of aspirin use at two-year intervals from baseline through the 2003 follow-up questionnaire ranged from 9.8 to 13%; in 2005, the prevalence was 10% for baby aspirin and 5.9% for other aspirin. Spearman correlation coefficients for report of regular aspirin use in a particular questionnaire with the subsequent questionnaire (i.e., 1995 with 1997, 1997 with Table 2 shows the associations of current use of aspirin, other NSAID, and acetaminophen at baseline with breast cancer risk, relative to non-use of each specific medication. The multivariable IRR (mIRR) for the association between current aspirin use at baseline and incident breast cancer was 0.90 (95% CI = 0.75, 1.07); the mIRR for C5 years of use was 0.78 (95% CI = 0.58, 1.05; p for trend = 0.15). We observed similar associations for current use of other NSAIDs (mIRR = 0.87; 95% CI 0.67, 1.13) and acetaminophen (mIRR = 0.90; 95% CI 0.76, 1.07). The mIRR for C5 years of use of acetaminophen was 0.87 (95% CI = 0.67, 1.12; p for trend = 0.17). The results did not materially change for current aspirin use (mIRR = 0.88; 95% CI = 0.73, 1.06) or acetaminophen use (mIRR = 0.90; 95% CI = 0.74, 1.10) when the reference category was no aspirin, other NSAIDs, or acetaminophen use. Table 3 shows the associations for time-varying use of aspirin, other NSAIDs, and acetaminophen with breast cancer risk during follow-up. The mIRRs were 0.79 (95% CI = 0.66, 0.95) for current use of aspirin compared with non-use of aspirin and 0.80 (95% CI 0.65, 0.98) for current acetaminophen use compared with non-use. The mIRRs for former use of aspirin and acetaminophen were compatible with 1.0. Longer duration (C5 years) of both aspirin (mIRR = 0.68; 95% CI = 0.50, 0.92; p for trend = 0.03) and acetaminophen (mIRR = 0.70; 95% CI = 0.51, 0.97; p for trend = 0.03) use was associated with greater reductions in breast cancer risk. The mIRR for current other NSAID use was 0.75 (95% CI = 0.55, 1.02).
Associations were little changed when we included baby aspirin use from the 2005 follow-up questionnaire in the time-varying analyses (data not shown). Results were similar among pre and postmenopausal women and among obese and non-obese women (data not shown).
The distribution of baseline characteristics by pain medication use among the subset of women who completed all questionnaire cycles was similar to that of the overall population. Among women who completed all questionnaire cycles, the associations for baseline current aspirin, other NSAIDs, and acetaminophen use were also similar to those in the overall population. For example, the mIRRs for C5 years use of aspirin and acetaminophen at baseline were 0.69 (95% CI = 0.49, 1.03) and 0.73 (95% CI = 0.53, 1.03), respectively, and the corresponding mIRRs for time-varying current aspirin and acetaminophen use were 0.76 (95% CI = 0.61, 0.94) and 0.81 (95% CI = 0.64, 1.02), respectively.
Discussion
In the present study, we observed a reduced risk of breast cancer among current aspirin users and a stronger association when aspirin use was updated over follow-up. The lowest risks were observed for women who used aspirin regularly for at least 5 years. Use of other NSAIDs and use of acetaminophen were also associated with a decreased breast cancer risk.
Findings from our study for use of aspirin and other NSAIDs are consistent with several previous prospective studies [12] [13] [14] [15] , but not others [16, [18] [19] [20] [21] . The Women's Health Initiative Observational Study observed a similar decreased risk of breast cancer for regular-strength aspirin or any NSAID use for C5 years of duration [12] . The Iowa Women's Health Study also observed a decreased risk of breast cancer for any aspirin use, particularly for frequent use (C6 times per week) [13] . The Vitamins and Lifestyle Cohort Study observed that regular-strength aspirin used for 1-3 years was inversely associated with breast cancer [14] . In addition, the large multicenter Case-Control Surveillance Study [35] and a case-control study of western New York [36] observed that NSAID use was associated with a reduced breast cancer risk. On the other hand, several large prospective studies have observed no association between aspirin or NSAID use and breast cancer risk [16, [18] [19] [20] [21] . The Women's Health Study randomized controlled trial reported no association between low-dose aspirin (100 mg) taken every other day for 10 years and breast cancer [21] . Compliance for taking low-dose aspirin or placebo was 67% over 10 years of follow-up [37] . The Nurses' Health Study and the NIH-AARP cohort study did not observe an association of aspirin with breast cancer risk [16, 20] . Two large nested case-control studies of the General Practices Research Database [38] and of Northern Denmark [39] did not observe an association between aspirin and breast cancer. Among premenopausal women in the Nurses' Health Study II, current use of aspirin and other NSAIDs was not associated with breast cancer [17] .
As in the present study, the Nurses' Health Study updated aspirin use over the course of follow-up [16] . The Nurses' Health Study assessed regular aspirin use as two or more aspirin pills taken per week, whereas our study assessed aspirin use at least 3 days per week. However, the Nurses' Health Study did not collect information on nonaspirin NSAIDs. While the inclusion of women with lower frequency of use per week and women who used other NSAIDs in the reference group could have biased their results toward the null, in our study, the results did not materially change when we compared aspirin, other NSAID, and acetaminophen use to the absence of use of all three pain medications.
Mixed findings have also observed specifically among African American women. The Carolina Breast Cancer Study reported an inverse association between all NSAIDs combined with breast cancer among African American women (379 cases), which was a stronger association than in White women [23] . An analysis of the Multiethnic Cohort Study data (289 cases) observed a null association for current and former aspirin use and a non-significant inverse association between non-aspirin NSAIDs use and breast cancer [19] . In follow-up studies with repeated data collection, there is a question as to how to treat missing data from cycles in which data were not provided. The relatively low correlation between aspirin use from one questionnaire cycle to the subsequent cycle in our study suggested that pain medication use varies considerably over time. Therefore, we assigned missing indicators for medication use for person-time in which a questionnaire was not completed. We also carried out an analysis confined to women who had completed all the questionnaires. The two methods gave similar results.
A limitation of our analysis was the absence of information on dose. Among the few existing studies that evaluated aspirin dose [3, 22, 40] , doses of [100 mg [12] and C325 mg [22] were associated with lower rates of incident breast cancer, whereas low-dose aspirin was not [21, 38, 39] . We asked about use of low-dose (''baby'') aspirin in 2005 only. Analyses that incorporated data on baby aspirin use gave similar results to analyses that did not include baby aspirin use in the exposure definition. We also lacked information on duration of analgesic medication use before 1995. Women who did not report current use in 1995, but had long-term use prior to 1995, would have been misclassified as non-aspirin, non-NSAID, or non-acetaminophen users, attenuating our results toward the null. Another limitation is that we defined ''regular'' use as use for three or more days per week, but this definition does not encompass the patterns of use that may be common among young to middle-aged women. For example, women may use analgesic medications for menstrual symptoms or intermittently for headaches or muscle aches. If these lower levels of use are also associated with a reduced risk of breast cancer, then inclusion of such women in the ''unexposed'' group would attenuate associations of analgesic use with breast cancer risk. BWHS questionnaires did not include a specific question on non-aspirin NSAID medications; therefore, nonaspirin NSAIDs may have been underreported in our study. Ibuprofen [12] and prescription NSAIDs [39, 41] have COX 2 inhibiting actions and have been associated with reduced breast cancer risk in some studies [12, 39, 41] . Inclusion of non-aspirin NSAID users in the reference group would have attenuated associations.
Our study found an inverse association between acetaminophen use and breast cancer, similar in magnitude to that for aspirin. While acetaminophen is not an NSAID, use was associated with reduced estradiol levels in a crosssectional analysis of the Nurses' Health Study [45] . In addition, acetaminophen has been shown to have antiinflammatory properties in laboratory studies [46] [47] [48] . Although most previous studies have not observed an association between acetaminophen use and breast cancer [12, 18, 19, 42, 43, 49] , two studies reported that acetaminophen was associated with a decreased breast cancer risk [4, 50] . In our study, the baseline descriptive characteristics for aspirin and acetaminophen use were similar and half of aspirin users at baseline also reported use of acetaminophen. This suggests that there may be other explanations for our inverse findings. The inverse associations observed in our study might reflect certain behaviors or characteristics associated with taking analgesic medications that are also associated with reduced breast cancer risk. Control for common conditions associated with pain medication use, such as rheumatoid arthritis, osteoarthritis, and cardiovascular disease, did not appreciably alter our results. However, unknown confounding may have distorted the results.
Our study is the largest to have assessed the associations of aspirin, other NSAIDs, and acetaminophen with incident breast cancer in African American women. Strengths include high participation rates over 12 years of follow-up, prospective data collection, detailed information on potential confounding variables, accurate breast cancer reporting, and a large number of breast cancer cases. Unlike the majority of studies examining the association between aspirin or NSAIDs and breast cancer [12-14, 18-20, 23, 44, 51] , we incorporated multiple observations per subject to allow for changes in medication use over follow-up. Our results were consistent, regardless of the method used to account for missing questionnaires over follow-up. Because of the potential for non-differential misclassification of medication use, our results may have underestimated the effect of these pain medications on breast cancer risk.
In conclusion, we observed that longer duration (C5 years) of current aspirin use is associated with a decreased risk of breast cancer in African American women. A similar inverse association with breast cancer incidence was observed for acetaminophen use. The reasons for the association with acetaminophen use are unclear. Further research may elucidate whether those results indicate that other factors such as indication for use of pain medications are responsible for the associations with both NSAIDs and acetaminophen or whether there is a beneficial biological effect of acetaminophen.
